Personal Tumor-Specific Neoantigen Vaccine Development

Neoantigen vaccines have shown encouraging results in terms of inducing neoantigen-specific T-cell responses. Creative Biolabs has established the high-throughput SuPrecision™ platform for large-scale whole exome sequencing (WES) services. Based on the WES data and a series of analysis, including somatic variant calling and human leukocyte antigen (HLA) typing, we can efficiently identify candidates for the development of neoantigen vaccines. We can provide the best service of personal neoantigen vaccine development at the most competitive cost.

The Background of Neoantigen Vaccine

Antigens are molecules that are displayed on the surface of cells and stimulate the immune system. Neoantigens are molecules on the cancer cells’ surface that are produced by DNA mutations. Studies show that neoantigens play an important role in mediating the destruction of tumor cells by the adaptive immune system. Effective anti-tumor immunity in humans has been associated with the presence of T-cells directed toward cancer neoantigens, which are T-cell epitopes with tumor-specific expression arising from non-silent somatic mutations. Neoantigens are highly immunogenic because they are not expressed in normal tissues and hence bypass central thymic tolerance, making them ideal targets for immune therapy against cancer. Although lots of attempts have been developed for effective cancer treatment vaccines, they mostly fail for producing potent antitumor immune responses. These vaccines have generally been made with tumor antigens that are too similar to antigens on normal cells. Consequently, the body generates immune tolerance, a weaker immune response to avoid harming normal cells. By contrast, the neoantigen vaccine is custom-made for each patient using antigens produced by mutations unique to the patient’s cancer and only present on cancer cells, thus bypassing the nature immune tolerance process.

Personal Neoantigen Vaccine Development Service at Creative Biolabs

Creative Biolabs can provide high-quality neoantigen vaccine development service based on our cutting-edge SuPrecision™ Platform. Workflow of developing a vaccine that targets personal neoantigens is as follow:

• Initiation with a study design and clinical assessments
• Performing WES of matched tumor and normal cell DNA from individual patients
• Identification somatic mutations and validate the expression of mutated alleles by RNA-sequencing
• HLA typing and selection
• Generation of personal neoantigen vaccine the purpose of tumor therapy
• Different types of neoantigen vaccines can be provided, including synthetic long peptide (SLP), dendritic cell, RNA and DNA neoantigen vaccines.

Key Advantages of Personal Neoantigen Vaccine Development Service Include but Are Not imited to:

• Diverse neoantigen vaccines types, including SLP, dendritic cell, RNA and DNA neoantigen vaccines
• Advanced WES technologies and computational algorithms
• Cutting-edge SuPrecision™
• Competitive and affordable price

Equipped with world-leading technology platforms and professional scientific staff, Creative Biolabs has accumulated rich experience in neoantigen vaccine development. We are pleased to share our cutting-edge technology and extensive expertise in personal neoantigen vaccine development to facilitate our clients’ related project development.

Please contact us for more information and a detailed quote.

Reference

1. Ott, P.A.; et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017, 547(7662):217-221.

1. Tumor Mutational Burden (TMB) Analysis for Response to Checkpoint Immunotherapy
2. Whole Exome Sequencing for Variants Analysis
3. Whole Exome Sequencing for Structural Variants Detection
4. Whole Exome Sequencing for Copy-Number Variants (CNVs) Detection
5. Whole Exome Sequencing for Tumor-Specific Neoantigens Discovery
6. Minimal Residual Disease (MRD) Monitoring Service
7. Whole Exome Sequencing for Biomarkers Discovery
8. Microsatellite Instability Analysis for Immunotherapy
9. Tumor Microenvironment Analysis by RNA-Seq
10. Immune Repertoire Germline Genes and Alleles Identification
11. One-stop Service for Cancer 3D Model
12. Circle-Seq-based eccDNA Identification